Jadiwon Tablet 25 Milligrams (Empagliflozin)

Adult dose

The recommended dosage of this medication is 10 mg once daily for monotherapy and additional combination therapy with insulin or other glucose-lowering agents. If tolerance to 10 mg of this medication is good and further blood sugar control is needed, the dosage may be increased to 25 mg once daily. This medication can be administered regardless of meals. The tablet should be swallowed whole. If a dose is missed, it should be taken as soon as remembered without taking a double dose in one day.

This medication should not be used in patients with allergic reactions to the active ingredient or other components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication is not to be used in patients with significantly reduced kidney function, specifically those with a glomerular filtration rate (GFR) of less than 30 mL/min/1.73 m2, end-stage renal disease, or those undergoing dialysis. This medication contains lactose, so it should not be given to patients with genetic issues such as lactose intolerance, lactase deficiency, or glucose-galactose malabsorption. In patients with mildly impaired kidney function, this medication should be given cautiously with regular monitoring of kidney function. Especially when the GFR is less than 60 mL/min/1.73 m2, dose adjustment may be necessary, and if it is less than 45 mL/min/1.73 m2, this medication should be discontinued. In heart failure patients, it should be used cautiously in mild to moderate cases and is not recommended for severe heart failure patients. When used in conjunction with insulin or sulfonylureas, adjustments may be necessary to manage hypoglycemia risk. During treatment with this medication, adverse reactions such as hypoglycemia, infections, particularly genital infections, increased urination, urinary tract infections, and decreased fluid volume may occur. Rarely, serious metabolic acidosis called ketoacidosis may occur, and immediate treatment should be sought if symptoms appear. Caution is needed for the elderly or those at high risk of fluid loss, as this medication may lower blood pressure or lead to dehydration. There is also a risk of serious infections such as urosepsis, pyelonephritis, and genital fungal infections, so symptoms should be monitored, and treatment administered if necessary. This medication may show a positive reaction in urine glucose tests, so caution should be taken in interpreting test results. Care is needed when driving or operating machinery due to the risk of hypoglycemia, especially when used in combination with insulin. Its use is not recommended during pregnancy, and administration should be discontinued once pregnancy is confirmed. If breastfeeding, it is advisable to discontinue nursing since this medication may be excreted in breast milk. Safety and efficacy have not been established in patients under 18 years of age, so it is not used in this population. In overdose situations, appropriate treatment should be provided based on the patient's condition, and methods to remove this medication via dialysis are not known. This medication should be kept out of the reach of children and should not be transferred to other containers.

Serious side effects

• Urticaria
• angioedema
• ketoacidosis
• urosepsis
• pyelonephritis
• perineal necrosis

Mild side effects

• Hypoglycemia
• vulvovaginal candidiasis
• balanitis
• and other genital infections
• itching
• rash
• increased urination
• urinary difficulty
• systemic and site reactions
• thirst

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1°C and 30°C at room temperature to preserve its effectiveness and safety for a longer period.

Appearance

Pale yellow oval film-coated tablet

Package unit

PTP - 10 tablets/PTP [(10 tablets/PTP×1)], PTP - 30 tablets/PTP [(10 tablets/PTP×3)]